Form D · Biotechnology
ENTEGRION INC
Durham, NC · CIK 0001392253
Offering snapshot reported Jul 6, 2022 · SEC filing
- Reported sold
- $13.9M Offering amount: $20M
- Investors reported
- 87 Form D · investor count
- Minimum accepted
- $0 Reported outside-investor minimum
- First sale
- Jun 30, 2022 As reported in this filing
What changed?
Latest filing versus its linked predecessor, where available.
No comparable changes in the displayed metrics.
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| Jul 6, 2022 | Initial | $13,865,829 | No comparison | 87 | SEC filing |
| May 16, 2019 | Amendment | $6,662,328 | $1,102,328vs Jul 6, 2017 | 73 | SEC filing |
| Jul 6, 2017 | Amendment | $5,560,000 | $1,360,000vs Oct 19, 2016 | 73 | SEC filing |
| Oct 19, 2016 | Amendment | $4,200,000 | $874,982vs Jun 6, 2016 | 59 | SEC filing |
| Jun 6, 2016 | Amendment | $3,325,018 | $2,798,544vs Nov 6, 2015 | 49 | SEC filing |
| Nov 6, 2015 | Initial | $526,474 | No comparison | 10 | SEC filing |
| Oct 11, 2011 | Amendment | $300,000 | $0vs Oct 7, 2011 | 4 | SEC filing |
| Oct 7, 2011 | Initial | $300,000 | No comparison | 4 | SEC filing |
| May 26, 2011 | Initial | $130,000 | No comparison | 5 | SEC filing |
| Mar 31, 2011 | Initial | $1,464,405 | No comparison | 42 | SEC filing |
| Oct 19, 2009 | Initial | $257,228 | No comparison | 5 | SEC filing |
| May 5, 2009 | Initial | $10,000 | No comparison | Not reported | SEC filing |
| Aug 22, 2008 | Paper | Not reported | No comparison | Not reported | SEC filing |
| Apr 17, 2008 | Paper | Not reported | No comparison | Not reported | SEC filing |
| Jun 5, 2007 | Paper | Not reported | No comparison | Not reported | SEC filing |
Offering details
- Securities
- Equity
- Exemptions
- 06b
- Duration over one year
- Yes
- Business combination
- No
- Sales commissions
- $0
- Finders' fees
- $0
- Form D file number
- 021-451250
Source: Form D, filed Jul 6, 2022. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No confirmed ADV fund connection is available for this issuer.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| Jeffery C. Basham | Executive |
| Romie Brownlee | Director |
| Les Brownlee | Director |
| R. Les Brownlee | Director |
| Robert Capps | Director |
| William Corbitt | Director |
| William S Corbitt Iii | Director |
| William S. Corbitt, Iii | Director |
| Joseph Da Corta | Executive |
| Thomas Edwards | Director |
| E. S. Eskridge, Jr. | Director, Executive |
| Michael Galiger | Executive |
| W Brian Gibler | Director |
| Brian Gibler | Director |
| Richard Kendall | Executive |
| J. True Martin | Director |
| Richard Martin | Executive, Promoter |
| James T. Martin | Director |
| J True Martin | Director |
| J. True Martin | Director |
| J. True Martin, Dr. | Director |
| John Mowell | Director |
| Patrick Nash | Director |
| Pierre Noel | Director |
| Stephen R. Petteway, Jr. | Director |
| Susan Reyer | Executive |
| Christopher Rumana | Director |
| Ronald Sacher | Director |
| Richard Sacher | Director |
| Norman E. Thagard | Director |
| Albert Valada | Director, Executive, Promoter |
Issuer details
Industry: Biotechnology (See others in industry)
Address:
4819 Emperor Blvd, Suite 400 Suite 170
Durham, NC, 27703
Durham, NC, 27703